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Abstract
Background: A chronic pancreatitis model was developed in young male Lewis rats fed a high-fat
and alcohol liquid diet beginning at three weeks. The model was used to assess time course and
efficacy of a replication defective herpes simplex virus type 1 vector construct delivering human
cDNA encoding preproenkephalin (HSV-ENK).
Results: Most surprising was the relative lack of inflammation and tissue disruption after HSV-ENK
treatment compared to the histopathology consistent with pancreatitis (inflammatory cell
infiltration, edema, acinar cell hypertrophy, fibrosis) present as a result of the high-fat and alcohol
diet in controls. The HSV-ENK vector delivered to the pancreatic surface at week 3 reversed
pancreatitis-associated  hotplate hypersensitive responses for 4–6 weeks, while control virus
encoding  β-galactosidase cDNA (HSV-β-gal) had no effect. Increased Fos expression seen
bilaterally in pain processing regions in control animals with pancreatitis was absent in HSV-ENK-
treated animals. Increased met-enkephalin staining was evident in pancreas and lower thoracic
spinal cord laminae I–II in the HSV-ENK-treated rats.
Conclusion: Thus, clear evidence is provided that site specific HSV-mediated transgene delivery
of human cDNA encoding preproenkephalin ameliorates pancreatic inflammation and significantly
reduces hypersensitive hotplate responses for an extended time consistent with HSV mediated
overexpression, without tolerance or evidence of other opiate related side effects.
Background
Chronic pancreatic pain has significant negative impact
on patient quality of life and mortality. Over 50% of
patients with idiopathic or alcoholic pancreatitis report
chronic severe pain, responsive initially to morphine or
synthetic opioids, but subject to development of tolerance
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to opiates, addiction and other intolerable side effects.
More effective, site-specific management of pain from
chronic pancreatitis would significantly impact patients'
pain levels, physical functioning, quality of life, general
health and survival given the high rate of suicide in
patients with this condition. The typical high fat diet of
the American public may contribute to even higher rates
of pancreatitis, particularly when combined with alcohol.
While alcohol ingestion has been used to induce animal
models of pancreatitis, reliable chronic pancreatitis mod-
els for translational studies are not available [1,2]. The
data produced in many current alcohol-fed pancreatitis
models is reported to be variable, and the models are
costly and time consuming to produce (~8 months). For
this study, we used 40-day-old Lewis rats fed a commercial
high fat liquid diet with 6% alcohol. The combined high-
fat and alcohol diet given to younger animals greatly
accelerated the induction of pancreatitis and allowed per-
sistence through the end of the study at 10 weeks. Hyper-
sensitive thermal responses developed in three weeks and
remained through ten weeks allowing study of the HSV
overexpression time course.
An explosion of interest in gene therapeutic approaches is
occurring as investigators assess the potential of molecular
targeting in a variety of clinical treatment approaches,
such as for cancer chemotherapy and nervous tissue repair
[3-5]. While both viral and non-viral approaches are
under study, viral oncolytic therapy (both alone and in
combination with conventional therapy) has been found
as safe, well tolerated, highly effective and efficient in clin-
ical trials as in animal studies. HSV-1, the common path-
ogen causing cold sores, is a class of double-stranded DNA
viruses with affinity for primary sensory neurons as do all
viruses of this class, including herpes zoster (HHV-3)
causing severe shingles pain. Both attenuated and replica-
tion-competent HSV have been used successfully in over
20 published Phase I/II clinical trials to date for prostate
cancer, glioblastoma, melanoma, leukemia and other
hematological malignancies [6-9]. Genetically engineered
replication-competent HSV-1 oncolytic transgene has
been safely delivered to patients who had failed prior ther-
apy. This includes i.v. delivery to patients with hepatic
colorectal metastases refractory to the first-line chemo-
therapy [9] and directly into tumors of the skin, breast,
head, neck, and gastrointestinal tract [10]. Histological
evidence of tumor shrinkage and necrosis is provided
[10]. Adenoviral mediated transfer of the IL-4 gene has
also been used to modify inflammatory cell invasion in a
chemically-induced model of pancreatitis [11].
While retroviral (lentivirus), adenoviral, adeno-associated
and herpes simplex viral vectors are currently under study,
advantages for use of herpes viral vectors have been
detailed [4,6,12-17]. Since minimal activation of immune
responses occurs to initial or prior HSV infections, severe
medical illness in immune-competent adults is rarely seen
as with other viral vectors, and anti-viral agents are avail-
able. Another advantage is that HSV-1 does not integrate
into the host genome, as do retroviral and adeno-associ-
ated viruses, so insertional mutagenesis is not a concern.
It efficiently delivers circular, non-replicating DNA extra-
chromosomally to the cell nucleus. Importantly, the large
HSV-1 cassette can easily be genetically engineered to
accommodate multiple transgene modules of any size up
to 150 kbp, including foreign DNA, cDNA, and even large
transcriptional regulatory sequences to provide cell type
specificity. Typically, the vector is loaded with CMV pro-
moter which amplifies its expression efficiency. HSV-1
can be rendered (1) replication conditional for added
control, (2) replication defective so it cannot produce
viral proteins required for productive infection or (3) rep-
lication-competent to prolong expression and perhaps
even allow advantageous reactivation. Utilizing the cell's
own machinery to "minipump" desired therapeutic
agents, HSV vectors can efficiently and effectively amplify
production of selected gene product(s) persisting on the
order of weeks-months in non-replicating neurons. Thus,
the HSV-1 transgene provides innumerable possibilities
for modification and customization to improve gene
delivery.
Our research goal was to assess the impact of met-
enkephalin overexpression in the high-fat and alcohol-
induced pancreatitis model using a replication defective
HSV vector to deliver human cDNA encoding pre-
proenkephalin. This same overexpression vector has been
used for uptake by primary afferent nociceptor endings via
a cutaneous route, resulting in diminution of nociceptive
behaviors in other models of inflammatory injury
[13,18,19]. In the current project, HSV-1 viral vectors are
applied directly to communicating sensory neurons in
inflamed pancreas after development of a hypersensitive
behavioral state induced with a high-fat and alcohol diet
in rats. Impressive abrogation of pancreatic inflammation
and hotplate hypersensitivity was detected in animals
receiving the HSV-ENK vector. Accompanying these find-
ings were increased tissue levels of met-enkephalin in tho-
racic spinal cord and pancreas (but not in cervical spinal
cord, liver, bladder or colon), and decreased Fos expres-
sion in spinal cord and midbrain. These findings support
previous assertions that gene therapeutic approaches are
useful clinical tools for extended treatment of chronic
inflammatory conditions [12,16,20], and indicate a key
role for met-enkephalin overexpression in tissue repair/
protection. Direct local use of HSV viral vectors clinically
would specifically avoid central nervous system encroach-
ment and the many unwanted side-effects of opiate use,
including tolerance.Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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Results
Pancreas of HSV-ENK-treated rats has normal 
histopathology
Histological examination of pancreata at ten weeks in rats
fed with high fat and alcohol diets and treated with vehi-
cle (Fig. 1B) or HSV-β-gal (Fig. 1C) demonstrated tissue
edema, steatosis, inflammatory cell infiltration, fibrosis,
and acinar necrosis in all rats from these two groups.
However, the pancreata of rats fed with alcohol and high
fat diet but treated with HSV-ENK (Fig. 1D) showed
reduced inflammatory cell infiltration and preservation of
pancreatic tissue architecture. As expected, no abnormal
acinar architecture was detected in the pancreas of naïve
control rats (Fig. 1A). Weight gain monitored weekly was
within 15–20% of littermates fed conventional lab chow
in accordance with IACUC regulations. Enzymes (amylase
and lipase), alcohol and glucose were measured in the
blood at the end of the ten week study. No differences
were found among the treatment groups. Blood alcohol
levels were 120.6 ± 35.4 mg/dL for high fat/alcohol treat-
ment groups compared to 4.75 ± 3.4 mg/dL for naïve rats.
HSV-ENK treatment decreases hotplate sensitivity in 
pancreatitis
Figure 2 demonstrates hot plate response latencies in rats
fed the high fat and alcohol diet over the course of the
study. Significant decreases in latency thresholds were
noted in all groups fed the high fat and alcohol diet at the
beginning of the third week indicating development of
hypersensitivity. At this time point, the viral vectors and
vehicle were applied to the pancreatic surface. In week 5,
a significant recovery of withdrawal latencies to near nor-
Histopathology of rat pancreas at week 10 Figure 1
Histopathology of rat pancreas at week 10. A. Naïve animals were fed low soy chow and given no treatment. B. Method 
control animals given the alcohol and high-fat diet to induce pancreatitis were given pancreatic injection of vehicle (DMEM) 
only. C. Some animals with alcohol and high-fat diet induced pancreatitis were given pancreatic HSV-β-gal applications, serving 
as the vector control. Note the steatosis, inflammatory cell infiltration, acinar cell necrosis, tissue edema, ductal widening and 
periductal fibrosis seen in the controls, with alcohol and high-fat diet induced pancreatitis given vehicle or the HSV-β-gal appli-
cations (B and C). D. Greatly reduced inflammatory cell infiltration and preservation of pancreatic tissue architecture was seen 
in animals fed the alcohol and high-fat diet but treated with the HSV-ENK vector. The histopathology of the HSV-ENK vector-
treated animals was similar to that of the naïve animals (A). Hemotoxylin and eosin (H&E) stain.Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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mal values was recorded for animals treated with HSV-
ENK (n = 7), compared to animals treated with vehicle (n
= 6) or HSV-β-gal vector (n = 7). The analgesic effect of
HSV-ENK vector treatment lasted at least 4 weeks (week
5–9) without the apparent development of tolerance. By
week 10, all groups fed the diet displayed significantly
shortened withdrawal responses compared to naïve rats,
indicating thermal hypersensitivity and decreased effect of
the met-enkephalin overexpression. Concurrent footpad
testing of thermal and mechanical sensitivity with Har-
greaves and von Frey tests were negative throughout the
ten week study indicating higher order rather than spinal
reflexive response changes for this model.
Increased met-Enkephalin (met-ENK) expression in spinal 
cord, DRG and pancreas in HSV-ENK-treated animals
The animals used for behavioral studies were sacrificed for
immunofluorescent localization studies at the end of
week 10. Naïve animals served as untreated controls with-
out pancreatitis. Spinal cord (T7–12), DRG (T7–9) and
pancreas tissues were examined for met-ENK, β-gal, and
HSV-1 immunoreactivity.
Immunostaining for met-ENK in the spinal cord of HSV-
ENK-treated animals at week 10 (Fig 3D, n = 4, 106.1 ±
32.9 arbitrary units) revealed increased densities in Lami-
nae I and II compared to that of HSV-β-gal-treated (Fig 3C,
n = 4, 50 ± 12.1 arbitrary units), vehicle-treated (Fig 3B, n
= 4, 31.7 ± 5.6 arbitrary units), or naïve animals (Fig 3A,
n = 3, 43.7 ± 4.4 arbitrary units). Quantification of the
Hot plate response latency nociceptive behavior measurements Figure 2
Hot plate response latency nociceptive behavior measurements. Hot plate response latency measurements are 
shown for naïve animals and animal groups with alcohol and high-fat induced pancreatitis. Hot plate test was conducted at 
baseline before induction of pancreatitis and for ten weeks subsequently. Note the significant shortening of hot plate response 
latencies for rats on the high fat and alcohol diet after week 3, indicating sensitization. The HSV-ENK treatment (arrow) signif-
icantly abrogated the shift in response latency for at least four weeks. Four weeks is typical of HSV vector expression.Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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staining confirmed a significant increase in met-enkepha-
lin stain density in HSV-ENK-treated animals (Fig 3E).
Staining for met-ENK in pancreata at week 10 revealed sig-
nificantly increased densities in HSV-ENK-treated animals
(Fig 4D, 954.6 ± 77.6 arbitrary units) compared to vehicle
or HSV-β-gal-treated animals with pancreatitis (Fig 4B and
4C, 452.2 ± 9.6 and 504.5 ± 18.2 arbitrary units, respec-
tively), or the naïve animals (Fig 4A) (402.1 ± 10.7 arbi-
trary units). Staining intensities for met-ENK were higher
in all animals with pancreatitis compared to naïve ani-
mals, particularly those receiving the viral vector. The
localization pattern for the met-enkephalin in pancreas
was diffuse and appeared granular within the acinar cells,
but localization in neuronal terminals and transversely
cut axons could not be ruled out.
Staining for met-ENK is observed in most DRG at week 10
(Fig 5). Higher levels of immunostaining were observed
in thoracic DRG of HSV-ENK-treated animals (Fig 5D)
compared to vehicle- (Fig 5B) or HSV-β-gal-treated (Fig.
5C) animals with pancreatitis, or the naïve animals (Fig
5A). Staining for β-galactosidase was only detected in the
cells of the thoracic DRG from the HSV-β-gal-treated rats
with pancreatitis (not shown).
HSV-1 Protein staining is expressed in DRG of HSV-ENK- 
and HSV-β-gal-treated animals
Staining for HSV-1 proteins in the thoracic DRG was
observed in many cells in the HSV-ENK- and HSV-β-gal-
treated animals in week 10, primarily in the sections illus-
trated in Figure 6 (Fig 6D and 6C, respectively). As
expected, vehicle-treated rats with pancreatitis (Fig 6B) or
naïve animals (Fig 6A) had negligible staining of HSV-1
proteins in the thoracic DRG. There was negligible back-
ground staining in the cervical DRG of the HSV-ENK- and
HSV-β-gal-treated animals (not shown). No immunos-
taining was detected for HSV-1 proteins in the thoracic
spinal cords from any of the groups of animals (not
shown). No HSV-1 proteins were detected by immunohis-
tochemistry in pancreas [see Additional file 1], liver [see
Additional file 2], duodenum, bladder or colon from any
of the treatment groups or naïve animals.
Decreased Fos expression in brains of HSV-ENK-treated 
animals
At week 10, increased numbers of cells with Fos immu-
nostained nuclei were seen bilaterally in the deep dorsal
horn and laminae X of spinal cord (T9–10) in the animals
with pancreatitis treated with vehicle (Fig 7B, 7F, 12.2 ±
2.9 cells per section) or HSV-β-gal (Fig 7C, 7G, 13.0 ± 2.0
cells). In contrast, the HSV-ENK-treated animals were
almost devoid of Fos staining in these areas (Fig 7D, 7H,
0.3 ± 0.1 cells), as in the naïve animals (Fig 7A, 7E, 0.4 ±
0.2 cells). In the brain stem, increased Fos expression was
seen bilaterally in the nuclei of cells of the ventrolateral
area of the periaqueductal grey and dorsal raphe nucleus
in the animals with pancreatitis treated with vehicle (Fig
8B, 28.5 ± 6 cells) or HSV-β-gal (Fig 8C, 40.4 ± 14.8 cells).
In contrast, the HSV-ENK-treated animals were almost
devoid of Fos staining in neuronal nuclei in these areas
(Fig 8D, 3.2 ± 2.3 cells), as in the naïve animals (Fig 8A,
5.4 ± 0.3 cells).
Decreased RANTES expression in the pancreas of HSV-
ENK-treated animals
Staining for the inflammatory mediator RANTES in the
pancreas revealed increased expression in the vehicle- and
HSV-β-gal-treated animals with pancreatitis at week 10
(Fig 9B and 9C, respectively). The RANTES staining
appears primarily confined to the inflammatory cells infil-
trating the pancreatic tissue. In contrast, there was negligi-
ble RANTES staining in the HSV-ENK-treated animals
with pancreatitis (Fig 9D) or naïve controls (Fig 9A).
µ-Opioid receptor expression in the pancreas
Staining density for µ-opioid receptor in the pancreas was
consistently low for all groups at week 10 (Fig 10A–D),
indicating no difference in µ-opioid receptor expression at
week 10. This is in contrast to high levels seen at one week
after HSV-ENK treatment in an acute pancreatitis model
[21]. No changes in substance P staining in the spinal cord
were seen at week 10, although we have observed
increased substance P receptor NK-1 expression one week
after acute, chemically induced pancreatitis [22].
Discussion
Overexpression of met-ENK observable both in spinal
cord and pancreas significantly improved pancreatic
inflammatory and histological outcomes, as well as
reversed hotplate hypersensitivity in a chronic pancreatitis
model induced with a high fat and alcohol diet in young
rats. Histologic signs of chronic pancreatic inflammation
evident in controls were not observed at ten weeks after
HSV-ENK treatment. Diet induced pancreatitis in controls
(with or without the HSV-β-gal control vector treatment)
was evident as fibrosis, edema, acinar necrosis, steatosis,
ductal widening, and inflammatory cell infiltration, with
no hepatic or Langerhans involvement. Hotplate sensitiv-
ity apparent after 3 weeks on the diet in all animals per-
sisted though the ten week study in controls, but was
attenuated for 4–6 weeks after HSV-ENK treatment with-
out tolerance or other adverse opiate symptomatology.
HSV-ENK-Treated animals demonstrated normal histology 
and decreased inflammation
The most intriguing finding in these studies was the rela-
tive preservation of pancreatic tissue in HSV-ENK-treated
rats fed the same high-fat and alcohol diet, compared to
the significant inflammatory tissue damage noted in theMolecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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met-Enkephalin immunohistochemical staining in spinal cord (T9–10) Figure 3
met-Enkephalin immunohistochemical staining in spinal cord (T9–10). A. The spinal cord from a naïve rat is shown 
for comparison to (B) the spinal cord of animals with diet-induced pancreatitis at week 10. C. The expression of met-ENK 
after application of vehicle or HSV-β-gal is similar to naïve rats (A). D. Met-ENK expression was significantly increased in HSV-
ENK vector-treated animals compared to controls. Met-ENK in the dorsal horn (laminae I–II) of the thoracic spinal cord was 
increased bilaterally.Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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met-Enkephalin immunohistochemical staining in pancreas Figure 4
met-Enkephalin immunohistochemical staining in pancreas. Photomicrographs and quantification of immunohisto-
chemical staining for met-enkephalin in pancreas are shown for week 10. Minimal or no staining is seen in pancreas of (A) naïve 
and (B-C) control animals with alcohol and high-fat diet induced pancreatitis. D. Met-ENK expression was significantly 
increased in the pancreas of HSV-ENK-treated animals fed the same diet compared to the controls.Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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vehicle and control vector-treated animals. The histologi-
cal preservation and/or restoration of pancreatic tissue is
coupled with decreased RANTES staining and inflamma-
tory cell invasion in HSV-ENK-treated animals relative to
vehicle and vector controls. Marked improvements in
inflammatory cell infiltrates and decreased inflammatory
mediator content (RANTES and COX-2) are seen after
HSV-ENK treatment in two additional animal models in
use in our laboratory (CFA arthritis and acute pancreatitis
[21]). Radiographic improvement after inflammatory
damage has been reported previously in arthritic animals
treated with this enkephalin-encoding vector in addition
to decreased periarticlar osteopenia [18]. There is abun-
dant evidence that opioid peptides delivered by infiltrat-
ing inflammatory cells contribute to tissue enkephalin
content with modest anti-inflammatory effects [23-28].
However, unlike synthetic opiates, met-enkephalin is
quickly degraded by endopeptidases and is not measurea-
ble in blood. It is important to note that over-expressed
met-enkephalin is delivered directly to target tissues by
nociceptive afferents affected by the HSV vector [19,29].
Previous experiments, using antisera against human pre-
proenkephalin, which does not cross-react with rodent
preproenkephalin have demonstrated gene product
expression in sensory neurons containing HSV protein
after peripheral administration of this human pre-
proenkephalin vector [13]. The impact of opiates deliv-
ered to the site of inflammation by the affected neuronal
endings has not previously been appreciated. Delivery of
significant quantities of exogenous met-enkephalin by
HSV vector-driven overexpression provides a means of
getting at this issue and by all appearances provides signif-
icant tissue protection. Enkephalin has been shown to
reduce release of substance P from dorsal root ganglia
met-Enkephalin immunohistochemical staining in thoracic DRG Figure 5
met-Enkephalin immunohistochemical staining in thoracic DRG. Photomicrographs of immunohistochemical staining 
for met-enkephalin in DRG (T7–9) of (A) naïve and control animals (B, C) with alcohol and high-fat diet induced pancreatitis at 
week 10. Minimal staining is typical of peptides in the absence of axonal transport inhibitors since they are rapidly transported 
to axonal terminals. D. Note the increased met-ENK staining in DRG of animals with HSV-ENK treatment fed the alcohol and 
high-fat diet, compared to the naïve and control animals. Intracellular staining appears primarily in small and medium sized cells 
of the T7–T9 DRG of the HSV-ENK treated animals.Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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cells in culture by blocking voltage gated Ca++ channels
[30], which would abrogate both nociceptive and neuro-
genic edema actions of substance P. We propose that it is
the continuous release by the neuronal endings of signifi-
cant levels of met-ENK, directly into pancreatic tissue in a
physiologically relevant manner that provides additive
effectiveness for tissue protection from inflammatory
responses imposed by the diet. Follow-up studies will be
required to assess the relevance of neuronally-released
met-enkephalin to the inflammatory response.
A protocol with accelerated alcohol associated 
pancreatitis
Pancreatitis is defined by the presence of inflammatory
mediators and inflammatory cells in the pancreas in his-
tological samples. The animal model provided here has
histopathology consistent with severe chronic pancreatitis
without mortality. The rapidly induced chronic pancreati-
tis, complete with fibrosis in three weeks, is likely acceler-
ated at this developmental stage since the pancreas of
young animals is ill equipped for this diet. Many previ-
ously reported pancreatitis models employing high fat
and alcohol diets in older rats take much longer to
develop, and pancreatitis is not consistently observed in
all animals. Animals given alcohol alone as adults can
take up to eight months to develop pancreatitis [1,2].
Modifications in this study from previously published
models [31,32] included initiation of high fat and alcohol
diet at an earlier age, incrementally increasing alcohol
concentration each week in the nutritionally balance com-
mercial diet to assure animals are able to maintain
increase in body weight and good health.
HSV-1 immunohistochemical staining in thoracic DRG Figure 6
HSV-1 immunohistochemical staining in thoracic DRG. Photomicrographs of immunohistochemical staining for human 
HSV-1 protein at week 10. No stain is evident in dorsal root ganglia of (A) naïve animals or (B) vehicle-treated animals fed the 
alcohol and high-fat diet. Note the presence of staining for human HSV-1 protein in DRG of animals given the (C) HSV-β-gal 
and (D) HSV-ENK vector treatments. Cytoplasmic localization is noted for HSV in DRG from vector treated animals only in 
lower thoracic ganglia (T7–T9).
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c-Fos immunohistochemical staining in thoracic spinal cord (T9–10) Figure 7
c-Fos immunohistochemical staining in thoracic spinal cord (T9–10). Photomicrographs and quantification of immu-
nohistochemical staining for c-Fos in nuclei of cells of the thoracic spinal cord (T9–10) are shown for week 10. Spinal cord dor-
sal horn is shown in A-D. Spinal cord lamina X is shown in E-H. Naïve rats have almost no nuclei staining for c-Fos (A, E). 
Significantly more nuclei staining for c-Fos are found in animals with diet-induced pancreatitis and application of vehicle (B, F) 
or HSV-β-gal (C, G). Few nuclei were stained for c-Fos in animals given the diet and application of HSV-ENK (D, H).Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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c-Fos immunohistochemical staining in periaqueductal grey Figure 8
c-Fos immunohistochemical staining in periaqueductal grey. Photomicrographs and quantification of immunohisto-
chemical staining for c-Fos in periaqueductal grey (PAG) (week 10). A. Few stained nuclei are evident in naïve rat. B. Signifi-
cantly more c-Fos labeled nuclei are evident in animals with diet-induced pancreatitis and application of vehicle, or (C) in 
animals with diet-induced pancreatitis and application of HSV-β-gal. D. Little or no staining for c-Fos is evident in animals given 
the diet and application of HSV-ENK.Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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The chronic pancreatitis model described here was
devised specifically to test the full time course of HSV viral
vector overexpression. Our accelerated diet-based chronic
pancreatitis model in young animals yields consistent
inflammatory pathology, does not require surgical
manipulation, is cost efficient and importantly does not
have the associated high mortality rate we observe with
acute chemical/surgically induced pancreatitis models.
Furthermore, the animals show no outward signs of dis-
comfort or weight loss, and thus studies can be blinded
through the three month time course of study. The diet
induced pancreatitis was mild enough to maintain a
healthy appearance in young animals for the study dura-
tion, did not produce spontaneous behavioral signs of vis-
ceral pain or altered pain thresholds as in other more
severe visceral pain models, and allowed blinded behav-
ioral testing. These data further support the observation
made previously that high fat diet causes pancreatic
inflammation in animals though longer times are
required for adult animals [33].
Hotplate sensitization
The pancreatitis model provided accelerated development
of hotplate sensitization within three weeks in all animals
tested. The hotplate test was well tolerated and allowed
determination of the full time course of the HSV mediated
met-enkephalin overexpression effect. This has not been
possible with other pancreatitis models which either
resolve within weeks or produce more severe pancreatitis
with multi-organ failure possible if allowed to persist.
Outright spontaneous pain behaviors were not evident in
these animals, nor were results positive for other conven-
tional pain-related behavioral tests, such as Hargreaves,
von Frey and open field tests, although our preliminary
RANTES immunohistochemical staining in pancreas Figure 9
RANTES immunohistochemical staining in pancreas. Photomicrographs of immunohistochemical staining of RANTES 
in the pancreas of rats are shown for week 10. A. Naïve rat pancreas. B. Diet-induced pancreatitis and application of vehicle as 
control. C. Diet-induced pancreatitis and application of the HSV-β-gal control vector. D. Animals given the same diet and appli-
cation of HSV-ENK. Note the increased RANTES staining in pancreata of animals with alcohol and high-fat diet induced pancre-
atitis treated with vehicle or HSV-β-gal applications. Little or no staining of RANTES is noted in naïve and HSV-ENK-treated 
animals.Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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tests indicate that these measures will be useful in
extended studies (over three months). Although there
have been few studies assessing hyperalgesia or allodynic
responses in humans, both chronic pancreatitis and pan-
creatic cancer produce secondary thermal hyperalgesia in
humans [34,35]. Chronic pancreatitis produces general-
ized deep hyperalgesia consistent with central sensitiza-
tion [36,37]. Most pain testing in patients using
mechanical and electrical stimulation, report heightened
responses, VAS scores and increased descriptive words for
the pain. There are at least 3 quality of life instruments
that have been used in pancreatitis related pathologies.
These include the SF-36, which is validated across coun-
tries, ethnicities and is non-organ specific. This test reflects
the physical and mental restrictions placed on the patient
secondary to generalized pain. There are also modified SF-
36 instruments focused for pancreatic cancer. The stand-
ard SF-36 includes a domain for bodily pain (BP), which
assesses general body pain. The normative value for BP is
>85 for most studies. Pancreatic pain patients usually
score around 40–50, which is significantly less, but
improvement in BP is due to therapeutic interventions.
The met-enkephalin-induced analgesia suggests that spi-
nal cord opiate receptors modulate transmission of vis-
ceral pain information that is being provided to higher
centers involved in the processing affective responses to
pain. Assessments of affective pain due to visceral pain are
considerably more difficult in preclinical testing. The hot-
plate test provokes complex higher level pain induced
responses (foot flick, paw licking, etc) mediated by
supraspinal as well as reflexive motor commands [38].
Tests relying primarily on reflexive spinal cord and brain-
stem responses to stimulation of cutaneous regions of the
abdomen or footpad were unaffected in this model, as
was noted in a tail amputation model previously [38].
Despite measurable blood alcohol levels, open field activ-
ity testing in the San Diego apparatus revealed no differ-
ences between groups through the ten weeks of testing.
This is reflective of the mild nature of the model which we
No µ-opioid-receptor staining in pancreas at 10 weeks Figure 10
No µ-opioid-receptor staining in pancreas at 10 weeks. Photomicrographs of immunohistochemical staining of µ-opi-
oid-receptor in pancreas of rats are shown at week 10. A. Naïve rat pancreas. B. Diet-induced pancreatitis and application of 
vehicle. C. Diet-induced pancreatitis and application of HSV-β-gal as HSV vector control. D. Pancreas from animals given diet 
and application of HSV-ENK. There was no significant positive staining in any of the four groups of animals.Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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have chosen for these chronic studies. It is likely that con-
tinuation of the high fat and alcohol diet would initiate
referred and secondary nociceptive sensitization. Erichsen
(see [39]) stated that pain from urinary bladder is some-
times referred to soles of the feet. Ness and colleagues [40]
have reported sensitization as far as the knees in rats after
repeated bladder distensions. The pancreas of rat is inner-
vated bilaterally by axons from dorsal root ganglia T6-L2
(primarily T9–T13, [41]. Kuo and De Groat [42] deter-
mined that splanchnic nerve innervating pancreas (and
other visceral organs) is composed of 90% unmyelinated
fibers. Nociceptive foot withdrawal in response to applied
heat occurs at about the same skin temperature as activa-
tion of nociceptors, thus response latency is an accurate
measure of changes in nociceptive threshold produced by
drug treatments [43-45]. Mechanosensitivity was not evi-
dent in this model, implying there was no recruitment of
peripheral Aδ or Aβ fibers or sensitization of central neu-
rons to this type of input. Previous studies have reported
differential hyperresponsivity for mechanical without
thermal sensitization [40,46-48]. An example of thermal
hyperalgesia alone was shown after gene transfer for over-
production of nerve growth factor (NGF). The NGF pro-
duced thermal and mechanical hyperalgesia in the
injected paw, but only thermal hyperalgesia in the unin-
jected paw [49]. Spinal sensitization mechanisms are
likely responsible, while higher level sensitization is
implied for the hotplate test. Meller and Gebhardt [50]
propose that differential responses indicate that different
mechanisms underlie thermal and mechanical hypersen-
sitivity. Thermal hyperalgesia occurs with N-methyl-D-
aspartate (NMDA) receptor mediated calcium-dependent
production of nitric oxide, while mechanical hyperalgesia
results from coactivation of alpha-amino-3-hydroxy-5-
methylisoxazole-5-propionate (AMPA) and metabotropic
glutamate receptor mediated cyclo-oxygenase products of
arachidonic acid metabolism.
It is well known that somatic and visceral pain differ sub-
stantially in perception. In particular, a classic feature of
visceral pain is referral to another part of the body [39],
often following a dermatomal pattern [51]. A previous
study reports thermal sensitivity of hindpaw after acute
bladder inflammation (50% turpentine for 1 hr) [52] and
provides review of two primary theories to explain
referred pain. The axon reflex theory proposed by Sinclair,
Weddell and Feindel in 1948 [53] stated that axons with
collateral branches innervating both somatic and visceral
targets may become sensitized sending erroneous mes-
sages to spinal cord. A second theory by Hardy and others
proposes convergence at a central site that becomes an
irritable focus [49,53-55]. The data presented in the
present study provide support for central viscerosomatic
convergence. Convergence of both visceral and somatic
input has been shown onto spinal neurons located in the
visceral processing region near the central canal (lamina
X) [56] that projects to regions of the brain involved in
processing of affective pain [57]. Thus, the hotplate test is
able to distinguish spinal and supraspinal (higher order
decision making) responses specific to visceral pain and
analgesia in this model. Mutant enk-/- mice are rendered
highly sensitive to the hotplate test while their baseline
responses to other nociceptive tests, such as tail-flick and
force swim, were unaffected [58]. When the knockout ani-
mals were challenged with acute pain as in the formalin
test or when normal animals are treated with naloxone,
nociceptive hyper-responsivity indicated a direct response
to the lack of enkephalin. Konig and colleagues [58] have
also speculated that opiates affect an anatomical pathway
for subjective pain rather than discriminative pain. Stud-
ies in humans show that opiates do not alter baseline
responses to pain (pain thresholds) but only the subjec-
tive experience of pain [59]. The present studies provide
support for a role by met-enkephalin in visceral pain
transmission and ultimately involvement in affective
responses to pain implying that subjective pain is not
entirely mediated by the many opiate receptors distrib-
uted at higher brain levels, including the limbic system.
HSV-ENK significantly reduced behavioral sensitization 
without tolerance for 4 weeks
Noxious thermal stimulation has been used to assess cen-
tral sensitization induced by various experimental models
of clinical pain syndromes [60-63]. In this study, the hot
plate test indicated hypersensitivity after three weeks on
the diet. Response latencies recovered within 2 weeks to
near-baseline levels in HSV-ENK-treated animals, but not
in animals treated with control HSV-β-gal virus or the
vehicle. The single HSV-ENK treatment provided an anti-
nociceptive effect persisting for at least 4 weeks (week 5–
9) without tolerance normally observed in rats with opi-
ate therapy. This overexpression time course and efficacy
profile is consistent with other HSV viral vector studies in
animal models of ongoing central sensitization
[13,64,65]. Thus, with further molecular manipulations,
these vectors have potential for treatment of chronic pain,
including visceral pain.
In a site-directed manner, pancreatic surface application
selectively and effectively provides met-enkephalin to the
same receptors on nerve ending receiving information
from the inflamed pancreas, thus potently contributing to
anti-nociception and tissue preservation/restoration.
Standard pain therapies relying on higher and higher lev-
els of circulating opiates, on the other hand, can result in
intolerable side-effects in patients and rapid development
of tolerance in rats within days. Differential effects are
noted with mu opiate treatments, however, when an
inflammatory model is used in rats [66,67]. Enkephalin
administration has also been shown to attenuate mor-Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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phine tolerance [68,69], though it is rapidly inactivated by
endopeptidases if administered by conventional routes.
The present study indicates that site specific overexpres-
sion of met-enkephalin is a suitable opiate replacement
therapy or adjunct to low dose morphine, and would
avoid intolerable systemic side-effects.
The gradual return of hyperalgesic responses (decreased
latency thresholds) was noted between weeks 8 and 10 to
the same levels seen in the control animals with pancrea-
titis, despite significantly high levels of met-enkephalin in
the dorsal horn and pancreas. This mismatch may be
either reflective of the development of tolerance by week
10 and/or diminishing synthesis of the transgene product
with increasing HSV latency. Alternatively, other plastic
changes may develop by ten weeks in the spinal cord of
the now adult rats related to descending facilitation path-
ways and/or the diverse population of receptors and tran-
scription factors known to have a role in the development
of tolerance [70-72]. The literature provides few clues for
the extended time course of the present study, so addi-
tional studies are warranted.
Fos expression in animals with pancreatitis
Expression of Fos protein in the nucleus is another estab-
lished indicator of cell activation, especially after noxious
stimulation [73-78], including visceral pain [79-82]. With
the exception of the HSV-ENK-treated animals, Fos
expression was present at ten weeks in spinal cord, ventro-
lateral periaqueductal gray (PAG) and dorsal raphe. These
regions are major central nervous system sites involved in
modulation of nociception and concomitant behavioral
and autonomic responses [83-85]. Noxious stimulation
of viscera has been shown to evoke significant increases in
Fos expression in the ventrolateral column of the PAG in
acute pain models [86-89,80,86-88]. Typically, enhanced
expression of Fos is reported for chronic pain models only
after another acute noxious stimulation is given [89]. The
presence of Fos at ten weeks in the control animals with
pancreatitis was unexpected and likely related to the per-
sisting inflammation that was providing continuous nox-
ious stimulation of pancreatic afferents. While significant
Fos expression was observed in hypersensitive control rats
fed high fat and alcohol diet (vehicle and HSV-β-gal con-
trols), little Fos was evident in animals treated with HSV-
ENK, even though the hotplate sensitivity was re-estab-
lished at ten weeks. It is likely that Fos protein detected by
the polyclonal antibody is a chronic Fos-related antigen
(FRAs; Ex. deltaFosB), a stabile protein that can persist for
months which served here as a biomarker for activation
only in groups with chronic ongoing pancreatic inflam-
mation and hypersensitivity as reported previously in
other inflammatory and restraint stress models [90-92].
This supports the role for met-enkephalin in long-term
visceral nociceptive processing and/or autonomic control
as previously speculated [93].
Interestingly, the Fos labeled nuclei in spinal cord of con-
trol animals with diet-induced pancreatitis were localized
in deeper laminae of the dorsal horn rather than superfi-
cial laminae as in some pain models, i.e. cutaneous and
neuropathic pain. Localization in deeper lamina has been
noted previously with bladder stimulation [94]. Abbadie
and Besson [95] speculated that deep laminar distribution
of Fos seen in their early CFA studies might denote
chronic versus acute noxious activation. We further spec-
ulate that deep tissue, whole body insults such as their
CFA injections at the base of the tail or pancreatitis in the
current study, activate cells deep in the dorsal horn and
around lamina X, in contrast to superficial cutaneous
insults which activate cells and inducing Fos in the super-
ficial dorsal horn. The deeper distribution of activated
cells is also consistent with visceral pain transmission by
(1) lateral spinothalamic tract cells in laminae IV, V and
VII and (2) post-synaptic dorsal column cells in laminae
III and X [96].
The role of opiate receptors in inflammation
No evidence of inflammation was seen at ten weeks in
HSV-ENK-treated animals, i.e. no inflammatory cell infil-
tration or RANTES, despite apparent decrease in antinoci-
ceptive effect of the vector at this time point. This apparent
contradiction may be related to clinical observations that
analgesic effectiveness of opiates can diminish due to
decrease of opiate receptors while other physiological
effects of opiates are sustained. Adverse sympathetic
effects occur in response to use of synthetic opioids in
patients even after development of tolerance to the anal-
gesic effects [97]. Therefore, anti-inflammatory and anal-
gesic effects of opioids may each have uniquely dedicated
mechanisms and time courses.
The improved histological findings for pancreatic tissues
after HSV-ENK in the present study were coincident with
decreased RANTES and COX-2 and increased met-
enkephalin staining. The anti-inflammatory effects of opi-
oids, including met-enkephalin, have been previously
reported, and met-enkephalin is believed to be the major
anti-inflammatory peptide of the preproenkephalin gene
products (for review see [28]). Studies have shown that
peripheral opioid receptor effects provided by blood
borne inflammatory cells are increased in efficacy and
potency during active inflammatory conditions, and a
role for neuronal opioid peptides in reduction of inflam-
matory mediators has also been reported [21,28,98-104].
The increase in efficacy during inflammation has been
shown to be true for reduction of RANTES in particular
[69,105]. A previous study has shown that met-enkepha-Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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lin is also protective against stress ulcers in the gastrointes-
tinal tract of rats [106].
The literature suggests the opioid-induced immunosup-
pression in peripheral target cells include both opioid
receptor-dependent and receptor-independent mecha-
nisms, although the mechanisms are not fully elucidated
at this time. While delta opiate receptors are abundant in
the pancreas, their usual role is as an indirect mediator of
the acinar secretory functions [107,108]. Delta-opioid
receptor agonists such as met-enkephalin do not affect the
stimulant effect of KCl on isolated pancreatic lobules or
acinar cells in vitro, rather they decrease pancreatic enzyme
secretion by inhibiting cholinergic transmission. No
labeled nerves were observed in the fragile samples from
the pancreas, nor were delta opiate receptor antibodies
available at the time of these studies. Mu opiate receptors
and met-enkephalin protein are found in the pancreas in
amounts equal to the brain homogenate [109], and since
they are normally involved in glucose metabolism their
localization is typically in the glucagon cells of the islets
of Langerhans. While mu opiate receptors were
unchanged at the end of the present long term study after
HSV-ENK administration, mu opiate receptors were
shown to be increased at one week in our previous study
in all animals with acutely inflamed pancreata [21]. The
mu opiate localization evident in the pancreatic acinar
cells one week after HSV-ENK is thus far unexplained. The
significance of the abundance of met-enkephalin in the
acini of the pancreas after HSV-ENK treatment in the
absence of any remaining evidence of HSV protein, how-
ever, suggest that the met-enkephalin is of neuronal origin
in agreement with previous studies with this vector or a
similar one where stimulated release product was meas-
ured peripherally or stained proximally in ligated periph-
eral nerves [19,29].
Conclusion
In conclusion, this study provides significant evidence for
anti-inflammatory or tissue preserving effects of met-
enkephalin transgene overexpression that are at least
partly independent of its analgesic properties. Other sig-
nificant contributory findings include demonstration of a
highly effective method for site specific reversal of inflam-
mation while using lower titers and direct tissue adminis-
tration and development of an easily induced chronic
pancreatic inflammation model. Sustained analgesia
without tolerance is evident for at least 4 weeks after direct
pancreatic application of recombinant preproenkephalin-
encoding HSV vector consistent with the pre-latency
expression duration for this vector. An important safety
issue is addressed, i.e. there was no evidence of spread of
HSV-1 centrally or peripherally other than into the appro-
priate level DRG. These studies provide important consid-
erations in developing safe and effective therapeutic
regimens for clinical pancreatitis and other conditions of
chronic inflammatory pain. Further molecular manipula-
tions will enable investigators to engineer viral therapies
balancing greater potency, increased duration, specificity
of intended effect, and safety. Re-occurrence of neurogen-
ically initiated inflammatory bouts is common with pan-
creatitis, underscoring the relevance of further research
toward understanding central and peripheral inflamma-
tory pain mechanisms. While improved anti-inflamma-
tory agents have become available in recent years, the
prolonged effectiveness observed with a single dose of the
neurotropic overexpression vector may in the future pro-
vide distinct advantages for some clinical applications in
reducing pancreatic inflammation and pain.
Methods
Animals and diet
All procedures are consistent with the guidelines of the
policies for Ethical Treatment of Research Animals pub-
lished by the International Association for the Study of
Pain, and were approved by the Animal Care and Use
Committee at our institution. Young male Lewis rats (42
days old) weighing between 125–150 g (Harlan Sprague-
Dawley, Houston, TX) were used for this study. Animals
were kept in a 23° ± 2°C room on a 12 h light-dark cycle,
three per cage until they received surgical procedures, at
which time they were kept one animal per cage. Animals
were divided into four groups: naïve, pancreatitis + vehi-
cle, pancreatitis + HSV-1 with preproenkephalin cDNA
(HSV-ENK), and pancreatitis + HSV-1 with β-galactosi-
dase cDNA as the control transgene (HSV-β-gal). As part
of the preliminary studies, animals were treated with HSV-
ENK or HSV-β-gal or vehicle and fed a normal low soy diet
(Teklab 8626, Harlan, Indianopolis). Results for these
controls were similar to results for naive controls. The
high-fat liquid diet used in this study (Micro-stabilized
alcohol rodent liquid diet mix, LD 101A with LD 104 Test-
Diet, Richmond, IN) prepared fresh each day consisted of
28% fat from corn oil and safflower oil, 30.3% protein,
5% fiber, vitamins and minerals added as a dry powder to
apple juice and 95% ethanol (4–6% alcohol).
Experimental protocol
On day 1, baseline behavioral tests were obtained. The
high-fat liquid diet with alcohol was initiated as follows:
4% alcohol for the 1st week, 5% for 2nd week, and 6% from
the 3rd to 10th week. In the beginning of the study, a rat
consumed a daily average of 50 grams of liquid diet. With
normal growth, a rat consumed between 74–109 grams of
liquid diet (17–25 grams dry diet) daily. The dose of alco-
hol was thus progressively increased from 4–6 g/rat/day.
Weight gain was monitored weekly. Pancreatic enzymes
(amylase and lipase), alcohol and glucose were measured
in the blood at the end of the study after ten weeks on the
high fat alcohol diet. Animals were observed closely everyMolecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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day and no evidence of alcohol intoxication (ataxic, leth-
argy) or stress (eye porphyrin excretion) was noted, allow-
ing these studies to be conducted under blinded
conditions. At the beginning of the 3rd week and after
behavioral testing, the viral vectors HSV-ENK (n = 7),
HSV-β-gal (n = 7), or vehicle (n = 6) were applied to the
pancreatic surface. Behavioral activities were monitored
on the 1st day of each week for all rats thereafter until they
were sacrificed at the end of the 10th week. Pancreas, liver,
duodenum, bladder and colon were obtained before per-
fusion and immerse fixed for tissue histology and immu-
nohistochemistry. Spinal cords (T7–12 and C6), dorsal
root ganglia (DRG, T7–12 and C6) and brains were
obtained for immunohistochemistry after transcardiac
perfusion with buffered saline (50 ml) and fresh phos-
phate buffered paraformaldehyde (4%).
Behavioral testing
The development of thermal hypersensitivity was meas-
ured by the hot plate test [110,111] in an Analgesiometer
apparatus (Columbus Instruments). Rats were gently
placed on a hot-plate with its anodized aluminum surface
set to 50°C by an observer blinded to the treatment
group. The response latency to nociceptive behaviors of
shaking or licking paws, or jumping from the hot plate
was recorded and animals removed immediately from the
hotplate. A cut-off time point of 20 s was used to diminish
the potential of thermal injury to the rats. Three trials sep-
arated by over ten minutes were averaged for each data
point. Repeated testing with naive Lewis rats did not
decrease with repeated testing or over time as we have
seen (and others report) for Sprague-Dawley rats. Alcohol
was removed from the test diet the evening prior to the
behavioral testing to minimize potential interference with
reflexive and motor testing. Pilot studies determined that
similar young animals fed on high fat diets (28%) alone
or alcohol ingestion with normal fat diets (10%) plus
alcohol did not develop nociceptive behaviors and were
comparable to animals fed a standard 10% fat diet. Over-
night withdrawal of alcohol from animals receiving nor-
mal diets did not change nociceptive behaviors relative to
alcohol naïve animals (not shown). This indicates that the
hotplate sensitivity was not an effect of the alcohol with-
drawal.
HSV-based viral vectors
The HSV-1 virus vector HSV-ENK was constructed by
insertion of an expression cassette containing the strong
constitutive human cytomegalovirus promoter (hCMV),
an SV-40 intron, the human cDNA encoding pre-
proenkephalin and an SV-40 polyadenylation site into a
shuttle plasmid containing flanking HSV DNA from the
thymidine kinase region (SnaB I insertion site). The line-
arized shuttle plasmid and Pac I-digested DNA from virus
DPZ was co-transfected into the complementing 7B cell
line and recombinants selected by limiting dilution as
described [112]. This virus is similar to another pre-
proenkephalin-encoding virus reported previously to
attenuate formalin-induced nociception and potentiate
benzodiazepine anxiolysis when injected into the central
nucleus of the amygdala [113,114]. Generation of the
control virus encoding β-galactosidase under control of
the hCMV promoter (named DZ or SHZ.1) has been
described [115]. These recombinant viral vectors are rep-
lication-defective, created using the KOS strain of HSV
with both copies of the ICP4-coding region (IE3 gene)
deleted [116]. This viral vector has been used in several
previous studies [13,19,65].
Micropunctate application of viral vector to the 
pancreatic surface
Rats were anesthetized with sodium pentobarbital (50
mg/kg ip) and underwent midline surgical laparotomy to
expose the pancreatic surface. Five microliters of treat-
ment media suspension contained 2 × 106plaque-form-
ing-units (pfu) of the HSV-1 viral vector and was diluted
(1:10) in vehicle media (Dulbecco's Modified Eagle
Medium, DMEM, with 1% glycerol) from stock. This dilu-
tion was determined in preliminary studies. Treatment
media was applied onto the surface of the pancreas below
the attached peritoneum using a 1/2 cc U-100 insulin
syringe (28 G 1/2). Two to three areas void of pancreatic
duct and blood vessels were selected for HSV vector appli-
cation by superficial punctate injection. After confirming
that there was no bleeding from the pancreas or in the
abdominal cavity, the abdominal muscle and skin were
sutured. Rats were monitored closely during recovery
from anesthesia and returned to the animal facility.
Histopathology of the pancreas
On the day of sacrifice at the end of ten weeks, rats were
deeply anesthetized with sodium pentobarbital (70 mg/
kg). The pancreas was collected from each rat before the
perfusion procedure, and washed with phosphate-buff-
ered saline (PBS, pH 0.1 M) several times to remove blood
elements, followed by immersion fixation in 4% parafor-
maldehyde for 1 to 2 days. Three fixed pancreata from
each group were transferred to a container with 70% alco-
hol and sent to the UTMB histology core for paraffin
embedding, sectioning and hematoxylin/eosin (HE)
staining. As tissue controls, liver, bladder and colon were
also processed and stained with H&E in the same manner
as described above. The tissues were examined and photo-
graphed with a microscope (Nikon Eclipse E1000)
equipped with a digital camera system (CoolSnap ES
Monochrome, Photometrics, Roper Scientific Inc., Tuc-
son, AZ) for histopathologic analysis.Molecular Pain 2008, 4:8 http://www.molecularpain.com/content/4/1/8
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Immunohistochemical methods
For immunohistochemical analyses, the deeply anesthe-
tized animals were perfused transcardially with 50 ml of
heparinized saline at 37° followed by 500 ml of cold (4°)
4% paraformaldehyde solution in 0.1 M phosphate buffer
(PB; pH 7.4). The brains, spinal cords, and DRG were
post-fixed using the same fixative at room temperature for
4 hours before cryoprotection in 0.1 M phosphate buff-
ered 30% sucrose solution overnight and embedding in
OCT compound. Spinal cords and brainstems were cut on
a sliding microtome (30 µm) and immunostained free
floating in simultaneous experimental groups. Pancreata
(n = 4 per group) and DRG sections were cut (10 µm) on
a cryostat and placed directly on glass slides for immunos-
taining. The sections were rinsed (6×) in 0.1 M PBS, first
incubated in 5% blocking serum at room temperature for
40 min and then, for 24 h in primary antibodies/1% NGS
containing Triton X-100. Primary antibodies used in
immunohistochemistry were titrated and used as follows:
anti-met-enkephalin (1:1000; BioMol, Plymouth Meet-
ing, PA), anti-HSV-1(1:500; DakoCytomation, Glostrup,
Denmark), anti-β-gal (1:1000; Abcam, Cambridge, MA),
anti-FOS (1:3000; Calbiochem La Jolla, CA), anti-
RANTES (Regulated on Activation, Normal T-cell
Expressed and Secreted;1:300; R&D System, Minneapolis,
MN), anti-µ-opioid receptor (1:4000; Chemicon, Temec-
ula, CA). Sections were washed three times in PBS and
then incubated with goat anti-rabbit secondary antibody
conjugated with Alexa Fluor 586 (1:1000, Molecular
Probes, Eugene, OR) for 1 h at room temperature. After
rinsing in PBS 3 times, sections were mounted onto gela-
tin-coated slides, air-dried, and coverslipped with Micro-
scope Cover Glass (Fisher, St Louis, Mo). Specificity of
immunostaining by each primary antibody was con-
firmed by negative staining when (1) the primary anti-
body was deleted or (2) normal rabbit serum was used as
a neutral antibody. All sections from the different animal
groups were processed at the same time with the same
solutions for each tissue type.
Quantification of staining density
For immunohistochemical quantification, data were col-
lected using a computer-based image capture and analysis
system (Meta-Vue, MetaMorph Imaging System, Molecu-
lar Devices Corp, Downington, PA) linked to a fluores-
cence microscope (Nikon Eclipse E1000, Lewisville, TX)
via a digital camera (CoolSnap ES Monochrome, Photo-
metrics, Roper Scientific Inc., Tucson, AZ). Under the
same conditions, stained sections were observed, phot-
omicrographs taken and stain densities quantified. The
average intensity of staining in the 5 to 6 best representa-
tive sections from each animal were measured to control
for artifacts in the tissue.
Statistical analysis
Data were expressed as the average values ± standard error
of the mean. Statistical analyses were performed using
Prism software (Prism Software Corporation, Irvine, CA).
Overall comparison with Kruskal-Wallis analysis of vari-
ance was used for the nociceptive behavioral data. Post-
hoc comparisons to naïve animals were done with the
Mann-Whitney U test among the HSV-ENK-, vehicle- and
HSV-β-gal-treated animals fed the high fat and alcohol
diet. Immunochemical density data have arbitrary units
so the Kruskal-Wallis overall comparison was used. Post-
hoc comparisons to naïve animals were done with the
Mann-Whitney U test among the HSV-ENK-, vehicle- and
HSV-β-gal-treated animals fed the high fat and alcohol
diet. A p value ≤ 0.05 was considered significant for all
comparisons.
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